Delivery Order SPE2DB22D1017-SPE2DB25FG8DJ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $57,542.31 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 29, 2025, with an ultimate completion date of July 30, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA, leveraging the company's position as a critical healthcare solutions provider. The award is structured as a child...
- The Defense Logistics Agency awarded a $25,953.24 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 12, 2025, for the supply of Dupixent 300 mg/2 ml pens (2 ml quantity). This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 13, 2025. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,245.02 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 14, 2025, with a completion date of July 15, 2025. This firm fixed price delivery order, issued without set-aside designation, represents a competitive award to a major pharmaceutical distributor serving federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $8,322.75. This firm fixed price delivery order, which is set to be completed by August 28, 2025, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-set-aside, competitively awarded contract issued under AmerisourceBergen's existing pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a $53,153.38 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on July 14, 2025, with completion targeted for July 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively procured...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $12,957.54 under firm fixed price terms. The delivery order, which represents a child contract under a larger vehicle, has an ultimate completion date of August 25, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award was made through competitive procedures...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a firm fixed price ceiling value of $8,586.48. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $3,298.32 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen (2 ml) on June 27, 2025, with an ultimate completion date of June 30, 2025. This competitive award (no set-aside used) carries firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8DJDelivery Order
The Defense Logistics Agency (DLA) awarded a $20,272.36 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. No set-aside designation was applied to this award. This delivery order falls under AmerisourceBergen's significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a global pharmaceutical support vehicle, the IDC enables the company to supply a comprehensive range of medications, vaccines, and medical supplies to military healthcare programs and other federal agencies including the Defense Health Agency and U.S. Coast Guard. Dupixent, a specialty pharmaceutical product used for treating eczema and asthma, exemplifies the specialized medications within AmerisourceBergen's federal pharmaceutical distribution portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.3k | 7/24/25 |